News
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
News
Pembrolizumab/lenvatinib active against urothelial carcinoma
SAN FRANCISCO – Early objective responses were sufficient to prompt a larger phase 3 trial of the TKI and immune checkpoint inhibitor combination...
News
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
News
Anthracycline-free regimen OK in HER2-negative early breast cancer
There were no differences in disease-free or overall survival or distant recurrence-free interval between regimens with or without epirubicin.
News
Rare, aggressive NSCLC type yields to pembrolizumab
SAN FRANCISCO – Pulmonary sarcomatoid carcinoma tumors have high mutational burden and PD-L1 expression, making them ideal targets for immune...
News
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Durable responses to ADC sacituzumab in mTNBC
An antibody-drug conjugate induced clinical responses in one third of patients with heavily pretreated metastatic triple-negative breast cancer....
News
Pembrolizumab extends Merkel cell PFS, OS
Patients with both Merkel cell carcinoma subtypes had significantly better survival with first-line pembrolizumab, compared with historical...
News
Breast cancer recurrence lower, survival better with dose-intensified regimens
Shorter chemotherapy cycles and sequential dosing were associated with lower recurrence rates and better breast cancer-specific survival.
News
Eltrombopag ‘cannot be recommended’ during AML induction
The thrombopoietin-receptor agonist was associated with worse outcomes, compared with placebo, during induction therapy for adults with AML.
News
Trial supports less aggressive myeloma treatment
A less intensive transplant and maintenance strategy proved equally effective as more aggressive approaches in patients with multiple myeloma.
News
ADT harms likely limited to men with CV comorbidities
WASHINGTON – Androgen deprivation therapy improves survival for men with high-risk cancers, but those with comorbid cardiovascular disease may be...
News
Therapy ups breast cancer survivors’ cardiac risks
WASHINGTON – Anthracycline-based chemotherapy, anti-HER2 agents, and radiation all increase the risk for subsequent heart disease in breast cancer...
News
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
News
Cost-of-care counseling can be done, but does it help?
Helping patients understand the costs of chemotherapy did not lessen financial distress.